Setting

Asia Pacific Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity

Published: 28 Apr 2021 | Report Code: 10247994 | Pages: 112

Asia Pacific small molecule active pharmaceutical ingredient (API) market will grow by 9.2% annually with a total addressable market cap of $537.3 billion over 2021-2027 owing to increasing incidences of diseases, development of companies engaged in the manufacturing of small molecule APIs, the increasing technological developments in manufacturing sector, and surge in healthcare expenditure amid COVID-19 pandemic. Highlighted with 33 tables and 52 figures, this 112-page report “Asia Pacific Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific small molecule API market in every aspect of the classification from perspectives of Source, Type, Therapeutic Area, Application, Manufacturer Type, and Country. Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Synthetic API o Branded Synthetic API o Generic Synthetic API • Semi-synthetic API • Natural Origin Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Standard API • High Potency API (HPAPI) o Branded HPAPI o Generic HPAPI Based on Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Metabolic Diseases • Other Applications Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. o Clinical Use o Commercial Use Based on Manufacturer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Pharmaceutical Companies • CMOs Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2017-2027. The breakdown of key national markets by Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Aurobindo Pharma Ltd. Cambrex Corporation Catalent, Inc. Dr. Reddy's Laboratories Ltd. GlaxoSmithKline plc Lonza Group Merck & Co., Inc. Mylan N.V. Novartis AG Pfizer Inc. Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Wuxi AppTec Co., Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	23
2.2 Major Growth Drivers	25
2.3 Market Restraints and Challenges	28
2.4 Emerging Opportunities and Market Trends	31
2.5 Porter’s Fiver Forces Analysis	35
3 Segmentation of Asia Pacific Market by Source	39
3.1 Market Overview by Source	39
3.2 Synthetic API	41
3.2.1 Branded Synthetic API	42
3.2.2 Generic Synthetic API	43
3.3 Semi-synthetic API	44
3.4 Natural Origin	45
4 Segmentation of Asia Pacific Market by Type	46
4.1 Market Overview by Type	46
4.2 Standard API	48
4.3 High Potency API (HPAPI)	49
4.3.1 Branded HPAPI	50
4.3.2 Generic HPAPI	51
5 Segmentation of Asia Pacific Market by Therapeutic Area	52
5.1 Market Overview by Therapeutic Area	52
5.2 Infectious Diseases	54
5.3 Oncology	55
5.4 Ophthalmology	56
5.5 Cardiovascular Disorders	57
5.6 Central Nervous System	58
5.7 Respiratory Disorders	59
5.8 Metabolic Diseases	60
5.9 Other Applications	61
6 Segmentation of Asia Pacific Market by Application	62
6.1 Market Overview by Application	62
6.2 Clinical Use	64
6.3 Commercial Use	65
7 Segmentation of Asia Pacific Market by Manufacturer Type	66
7.1 Market Overview by Manufacturer Type	66
7.2 Pharmaceutical Companies	68
7.3 CMOs	70
8 Asia-Pacific Market 2020-2027 by Country	72
8.1 Overview of Asia-Pacific Market	72
8.2 China	75
8.3 Japan	77
8.4 India	80
8.5 Australia	82
8.6 South Korea	84
8.7 Rest of APAC Region	86
9 Competitive Landscape	88
9.1 Overview of Key Vendors	88
9.2 New Product Launch, Partnership, Investment, and M&A	91
9.3 Company Profiles	92
Aurobindo Pharma Ltd.	92
Cambrex Corporation	94
Catalent, Inc.	95
Dr. Reddy's Laboratories Ltd.	96
GlaxoSmithKline plc	97
Lonza Group	98
Merck & Co., Inc.	99
Mylan N.V.	100
Novartis AG	101
Pfizer Inc.	102
Sun Pharmaceutical Industries Ltd.	103
Teva Pharmaceutical Industries Ltd.	104
Wuxi AppTec Co., Ltd.	105
10 Investing in Asia Pacific Market: Risk Assessment and Management	106
10.1 Risk Evaluation of Asia Pacific Market	106
10.2 Critical Success Factors (CSFs)	109
Related Reports and Products	112
List Of Tables

Table 1.  Snapshot of Asia Pacific Small Molecule API Market in Balanced Perspective, 2020-2027	18
Table 2. Growth Rate of World GDP, 2020-2022	22
Table 3.  Main Product Trends and Market Opportunities in Asia Pacific Small Molecule API Market	31
Table 4. Asia Pacific Small Molecule API Market by Source, 2017-2027, $ mn	39
Table 5. Asia Pacific Small Molecule API Market: Synthetic API by Drug Type, 2017-2027, $ mn	41
Table 6. Asia Pacific Small Molecule API Market by Type, 2017-2027, $ mn	46
Table 7. Asia Pacific Small Molecule API Market: HPAPI by Drug Type, 2017-2027, $ mn	49
Table 8. Asia Pacific Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn	52
Table 9. Asia Pacific Small Molecule API Market by Application, 2017-2027, $ mn	62
Table 10. Asia Pacific Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn	66
Table 11. APAC Small Molecule API Market by Country, 2017-2027, $ mn	73
Table 12. China Small Molecule API Market by Type, 2017-2027, $ mn	76
Table 13. China Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn	76
Table 14. China Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn	76
Table 15. Japan Small Molecule API Market by Type, 2017-2027, $ mn	79
Table 16. Japan Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn	79
Table 17. Japan Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn	79
Table 18. India Small Molecule API Market by Type, 2017-2027, $ mn	81
Table 19. India Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn	81
Table 20. India Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn	81
Table 21. Australia Small Molecule API Market by Type, 2017-2027, $ mn	83
Table 22. Australia Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn	83
Table 23. Australia Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn	83
Table 24. South Korea Small Molecule API Market by Type, 2017-2027, $ mn	85
Table 25. South Korea Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn	85
Table 26. South Korea Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn	85
Table 27. Small Molecule API Market in Rest of APAC by Country/Region, 2017-2027, $ mn	87
Table 28. Aurobindo Pharma Ltd.: Company Snapshot	92
Table 29. Aurobindo Pharma Ltd.: Business Segmentation	92
Table 30. Aurobindo Pharma Ltd.: Product Portfolio	93
Table 31. Aurobindo Pharma Ltd.: Revenue, 2017-2019, $ mn	93
Table 32.  Risk Evaluation for Investing in Asia Pacific Market, 2020-2027	107
Table 33. Critical Success Factors and Key Takeaways	110
List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027	17
Figure 5. Asia Pacific Small Molecule API Market, 2017-2027, $ mn	20
Figure 6. Impact of COVID-19 on Business	23
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Small Molecule API Market	25
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Small Molecule API Market	28
Figure 9. Investment Opportunity Analysis	32
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Small Molecule API Market	35
Figure 11. Breakdown of Asia Pacific Small Molecule API Market by Source, 2020-2027, % of Revenue	39
Figure 12. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Source, Value ($ mn) and Share (%)	40
Figure 13. Asia Pacific Small Molecule API Market: Synthetic API, 2017-2027, $ mn	41
Figure 14. Asia Pacific Small Molecule API Market: Branded Synthetic API, 2017-2027, $ mn	42
Figure 15. Asia Pacific Small Molecule API Market: Generic Synthetic API, 2017-2027, $ mn	43
Figure 16. Asia Pacific Small Molecule API Market: Semi-synthetic API, 2017-2027, $ mn	44
Figure 17. Asia Pacific Small Molecule API Market: Natural Origin, 2017-2027, $ mn	45
Figure 18. Breakdown of Asia Pacific Small Molecule API Market by Type, 2020-2027, % of Revenue	46
Figure 19. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Type, Value ($ mn) and Share (%)	47
Figure 20. Asia Pacific Small Molecule API Market: Standard API, 2017-2027, $ mn	48
Figure 21. Asia Pacific Small Molecule API Market: High Potency API (HPAPI), 2017-2027, $ mn	49
Figure 22. Asia Pacific Small Molecule API Market: Branded HPAPI, 2017-2027, $ mn	50
Figure 23. Asia Pacific Small Molecule API Market: Generic HPAPI, 2017-2027, $ mn	51
Figure 24. Breakdown of Asia Pacific Small Molecule API Market by Therapeutic Area, 2020-2027, % of Revenue	53
Figure 25. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Therapeutic Area, Value ($ mn) and Share (%)	53
Figure 26. Asia Pacific Small Molecule API Market: Infectious Diseases, 2017-2027, $ mn	54
Figure 27. Asia Pacific Small Molecule API Market: Oncology, 2017-2027, $ mn	55
Figure 28. Asia Pacific Small Molecule API Market: Ophthalmology , 2017-2027, $ mn	56
Figure 29. Asia Pacific Small Molecule API Market: Cardiovascular Disorders, 2017-2027, $ mn	57
Figure 30. Asia Pacific Small Molecule API Market: Central Nervous System, 2017-2027, $ mn	58
Figure 31. Asia Pacific Small Molecule API Market: Respiratory Disorders, 2017-2027, $ mn	59
Figure 32. Asia Pacific Small Molecule API Market: Metabolic Diseases, 2017-2027, $ mn	60
Figure 33. Asia Pacific Small Molecule API Market: Other Applications, 2017-2027, $ mn	61
Figure 34. Breakdown of Asia Pacific Small Molecule API Market by Application, 2020-2027, % of Revenue	62
Figure 35. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Application, Value ($ mn) and Share (%)	63
Figure 36. Asia Pacific Small Molecule API Market: Clinical Use, 2017-2027, $ mn	64
Figure 37. Asia Pacific Small Molecule API Market: Commercial Use, 2017-2027, $ mn	65
Figure 38. Breakdown of Asia Pacific Small Molecule API Market by Manufacturer Type, 2020-2027, % of Revenue	66
Figure 39. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Manufacturer Type, Value ($ mn) and Share (%)	67
Figure 40. Asia Pacific Small Molecule API Market: Pharmaceutical Companies, 2017-2027, $ mn	68
Figure 41.  Breakdown of Asia Pacific Small Molecule API In-house Synthesis Market by Region, 2020-2027, % of Revenue	69
Figure 42. Asia Pacific Small Molecule API Market: CMOs, 2017-2027, $ mn	70
Figure 43.  Breakdown of Asia Pacific Small Molecule API Contract Synthesis Market by Region, 2020-2027, % of Revenue	71
Figure 44. Breakdown of APAC Small Molecule API Market by Country, 2020 and 2027, % of Revenue	73
Figure 45. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)	74
Figure 46.  Small Molecule API Market in China, 2017-2027, $ mn	75
Figure 47.  Small Molecule API Market in Japan, 2017-2027, $ mn	78
Figure 48.  Small Molecule API Market in India, 2017-2027, $ mn	80
Figure 49.  Small Molecule API Market in Australia, 2017-2027, $ mn	82
Figure 50.  Small Molecule API Market in South Korea, 2017-2027, $ mn	84
Figure 51.  Small Molecule API Market in Rest of APAC, 2017-2027, $ mn	86
Figure 52. Growth Stage of Asia Pacific Small Molecule API Industry over the Forecast Period	88
Key Players (this may not be a complete list and extra companies can be added upon request): 
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent, Inc.
Dr. Reddy's Laboratories Ltd.
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
 (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)